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Abstract
The prevalence of diabetes is increasing worldwide, and one of the most important 
complications, diabetic nephropathy, constitutes a significant global health care and 
socioeconomic burden. Glomerular dysfunction is a major factor in the development and 
progression of diabetic nephropathy. However, emerging evidence suggests that tubu-
lar damage also plays an important role in the pathogenesis of diabetic nephropathy. 
This tubulocentric view shifts the focus markedly from glomeruli to proximal tubules, 
which might have an important role as a trigger or a driver in the early development and 
progression of diabetic nephropathy. Accordingly, numerous studies have focused on 
several different tubular damage markers that are clinically indicated as potential bio-
markers for the early detection of diabetic nephropathy. Furthermore, these findings are 
relevant for identifying therapeutics for diabetic nephropathy that target the proximal 
tubules. This review outlines new tubulocentric insights into diabetic nephropathy, from 
pathophysiological mechanisms to diagnostic and therapeutic approaches.
Keywords: biomarkers, diabetic nephropathy, glomerulus, proximal tubules,  
SGLT2 inhibitors
1. Introduction
Diabetes is often accompanied by chronic kidney disease (CKD) and accounts for more than 
half of the cause of end-stage renal disease (ESRD) and dialysis [1]. With the increasing 
prevalence of diabetes and high morbidity and mortality, its complications such as diabetic 
nephropathy impose great burden on individuals with diabetes and their society as well [2]. 
It is unclear whether the glomerulus or tubules are more important in the development and 
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progression of diabetic nephropathy. The phenomenon of glomerulosclerosis led to an inter-
est in the glomerulus as the primary site of injury in diabetic nephropathy. Indeed, changes in 
glomerular structure, such as glomerular basement membrane thickening, mesangial expan-
sion, and nodular/global glomerulosclerosis, are key findings for the diagnosis of diabetic 
nephropathy and other forms of glomerulonephropathy [3]. Although changes in the glom-
erulus in diabetic neuropathy undoubtedly occur, there is growing evidence to suggest a 
prominent role for the proximal tubules as triggers or drivers of diabetic nephropathy. Indeed, 
this evidence provides a new perspective on the natural course and pathophysiology of dia-
betic nephropathy. These novel insights also provide new opportunities for diagnostic and 
therapeutic progress through targeting the proximal tubules in diabetic nephropathy. This 
review provides an outline of diabetic nephropathy, from the underlying pathophysiological 
mechanism to diagnostic and therapeutic approaches, based on a tubulocentric perspective.
2. Natural course of diabetic nephropathy: old and new
It is very important to understand the natural course of disease to ensure that technical 
advances are fully exploited. However, the natural course of diabetic nephropathy is complex 
and depends on several factors, such as the clinical treatments used, and the race, type of 
diabetes, and comorbidities of the patient. Therefore, it is difficult to treat and prevent diabetic 
nephropathy. Current treatments include renin-angiotensin system (RAS) blockade, antihy-
pertensives, glycemic control, and correction of dyslipidemia for the management of diabetic 
complications. Diabetes mellitus (DM) has a long history and was first described in 1552 BC; 
it has long been recognized as a socioeconomic burden [4]. Diabetes is regarded as a meta-
bolic derangement and is closely related to renal dysfunction, as a microvascular complication 
[5]. Classically, diabetic nephropathy has a five-stage natural history: hyperfiltration, silent 
nephropathy, incipient nephropathy (microalbuminuric stage), overt nephropathy (macroal-
buminuric stage), and ESRD [6, 7]. These five stages are almost exclusively applied to discus-
sions of type 1 diabetes since the precise onset of disease in type 2 diabetes is not known. This 
natural course of diabetic nephropathy has served as a basis for clinical practice, and there 
are ongoing efforts to reduce albuminuria in patients with type 2 diabetes and renal dysfunc-
tion. Most adult cases of diabetes are type 2, and it is critical to delineate the progress of this 
disease. Type 2 diabetes differs from type 1 diabetes in several aspects. First, it is impossible to 
determine disease onset in type 2 diabetes. Second, in many cases, hypertension and albumin-
uria commonly accompany type 2 diabetes. Third, microalbuminuria has a lower predictive 
value for renal dysfunction because of the high mortality rate caused by cardiovascular disease 
[7, 8]. Recently, a new paradigm was suggested for exploring the natural course of diabetic 
nephropathy in the context of microalbuminuria and the nonclassical form of the disease.
2.1. Microalbuminuria: moderately increased albuminuria
Microalbuminuria is a robust indicator of the onset and progression of diabetic nephropathy, 
and it is assessed by reference to serum creatinine levels or the estimated glomerular filtration 
rate (eGFR). However, microalbuminuria has some major limitations as a predictor of renal 
dysfunction [9]. Albuminuria measurements can be imprecise and vary widely according to 
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the assay method used, the time of urine collection, and the presence of clinical conditions such 
as fever, urinary tract infection, and congestive heart failure, as well as by exercise status [10]. 
Microalbuminuria was originally considered a subcategory denoted by an albuminuria level of 
30–299 mg/day in a 24-h urine sample or 30–299 mg/g creatinine in a spot urine sample. Recently, 
normoalbuminuria and microalbuminuria were replaced by “normal to mildly increased 
albuminuria” and “moderately increased albuminuria,” respectively, because albuminuria is 
directly related to all-cause mortality, cardiovascular mortality, and renal dysfunction, even in 
patients with normoalbuminuria and microalbuminuria [11, 12] Furthermore, microalbumin-
uria shows dynamic characteristics (Figure 1), being a transient state that can progress to mac-
roalbuminuria or regress to normoalbuminuria [13, 14]. A 7-year prospective study performed 
by the EURODIAB IDDM Complications Study Group in 352 type 1 diabetic patients showed 
that ~14% progressed to macroalbuminuria, 35% remained in a microalbuminuric state, and 
51% regressed to normoalbuminuria [13]. The Joslin study reported that 58% of 386 type 1 dia-
betic patients with persistent microalbuminuria regressed to normoalbuminuria [14]. A better 
glycemic control contributes to the regression of microalbuminuria, and almost half of patients 
with microalbuminuria can regress to normoalbuminuria, as evidenced by the above two large 
studies. Although microalbuminuria is caused by glomerular injury, recent research has focused 
on the role of tubular dysfunction in albuminuria in type 1 diabetes. The Second Joslin Kidney 
Study reported that kidney injury molecule-1 (KIM-1) and N-acetyl-β-D-glucosaminidase 
(NAG) levels were important for predicting the regression of microalbuminuria [15]. This find-
ing supports the theory that tubular injury plays a significant role in the progression of renal 
complications in type 1 diabetes. This pattern of microalbuminuria regression could also be 
applicable to type 2 diabetes, although no concrete evidence for this has been reported.
Figure 1. A triangle concept toward kidney function. eGFR, estimated glomerular filtration rate.
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In 216 Japanese patients with type 2 diabetes and microalbuminuria, the regression rate to 
a normoalbuminuric state was ~50%, where regression was associated with a RAS-blocking 
agent, a better glycemic control, and a tight control of blood pressure [9]. However, none of 
60 patients with type 2 microalbuminuric diabetic nephropathy regressed to normoalbumin-
uria in an African-American population [16]. This suggests that there are racial differences 
in changes in microalbuminuria status in type 2 diabetes, and further studies are needed 
to explore the role of genetic predisposition and race. A recent study suggested that macro-
albuminuria and microalbuminuria can regress to microalbuminuria or normoalbuminuria, 
respectively [17]. In the FinnDiane study, 23.4% of 475 type 1 diabetic patients with macroal-
buminuria regressed to a lower categorical albuminuric state and 2.5% regressed to normoal-
buminuria, although the statistical power was low [17]. Such regression would improve the 
cardiovascular prognosis and all-cause mortality. Previous studies proposed that the regres-
sion of microalbuminuria contributes to a reduction in renal or cardiovascular risk in type 
2 diabetic and hypertensive patients [18, 19]. These data suggest that it is necessary to treat 
diabetic patients with some degree of albuminuria to regress the albuminuria.
2.2. Nonalbumin proteinuria
Protein in urine comprises albumin (40%) and nonalbumin proteins (NAPs; 60%). A third 
of NAPs are low-molecular weight proteins (LMWP), such as light-chain immunoglobulins 
(20%), and two-thirds are Tamm-Horsfall mucoproteins produced by the distal tubules [20, 21]. 
The proportional contribution of albumin attributes to be largely more variable at lower levels 
of proteinuria, and NAPs are important when assessing proteinuria as a biomarker of renal 
tubular damage [22]. Nonalbumin proteinuria can be defined as an albumin excretion rate 
(AER) of < 30 mg/24 h with a protein excretion rate (PER) of >149 mg/24 h. Nonalbumin pro-
teinuria can be quantified in random spot urine samples using the following formula: NAP-
to-creatinine ratio (NAPCR) = protein creatinine ratio (PCR) − albumin creatinine ratio (ACR). 
Because albuminuria tests could miss up to 40% of females and 30.8% of males in the general 
population with gross proteinuria, NAP levels should be checked to accurately assess renal 
damage [21]. Our laboratory reported that urinary NAPCR had a significant association with 
the decline in eGFR of 237 type 2 diabetic patients with preserved kidney function and normo-
albuminuria [23]. In addition, NAP was related to tubular biomarkers such as KIM-1, neutro-
phil gelatinase-associated lipocalin (NGAL), and liver-type fatty acid-binding protein (L-FABP) 
in early type 2 diabetic nephropathy patients with preserved kidney function (eGFR ≥60 mL/
min/1.73 m2) [24]. Moreover, NAPCR could serve a simpler and a more practical marker for 
assessing the progression of renal dysfunction compared with laboratory urinary biomarkers, 
such as KIM-1, NGAL, and L-FABP [25]. In the future, it will be necessary to study NAP in 
diabetic nephropathy to discover novel processes in and investigate the course of the disease.
2.3. Normoalbuminuric renal decline (NARD)
In general clinical practice, the eGFR should be calculated at least once a year to properly manage 
diabetic patients. Like albuminuria, eGFR has some major limitations for predicting renal dys-
function, because serum creatinine and cystatin C levels cannot be measured precisely and do 
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not reflect early changes in the kidney. However, currently, there are no available tools that are 
more powerful for assessing kidney function. Although the classic course of diabetic nephropa-
thy involves sequential dysfunction of the kidney following albuminuria, recent epidemiologic 
data suggested the presence of normoalbuminuric diabetic nephropathy in some patients [26]. 
There is a close relationship between albuminuria and progressive dysfunction of the diabetic 
kidney. A recent Japanese study showed that a rapid decline in kidney function occurred in sub-
jects with higher levels of ACR of ≥3000 mg/g creatinine in urine. In addition, the rate of annual 
decline in eGFR was doubled in macroalbuminuric versus normoalbuminuric diabetics for 
9.2 years [11]. However, the focus should be on NARD with respect to early intervention strate-
gies, because dipstick tests cannot reveal low levels of albuminuria or NAP. The UK Prospective 
Diabetes Study (UKPDS) reported that, among the patients who developed renal impairment 
during the study, 61% did not have albuminuria beforehand and 39% never developed albu-
minuria [27]. This suggests that distinct pathobiological mechanisms may underlie NARD and 
albuminuric renal decline. The prevalence of NARD was not low (20.5–63%) in several clinical 
trials performed in type 2 diabetic patients [26]. Interestingly, in another study, the prevalence 
of retinopathy was lower in the NARD group than in the albuminuric group, and patients with 
NARD had a shorter duration of diabetes [28]. This finding gives rise to a new hypothesis, in 
which NARD is not to be related to microangiopathy and instead shows a greater association 
with tubulointerstitial damage or macroangiopathy (i.e., arteriosclerosis).
Most diabetic patients with albuminuria show typical renal pathological changes, whereas 
typical diabetic glomerular changes are observed less frequently. In addition, atypical histologic 
changes suggestive of a severe interstitial or a tubular damage, or varying degrees of arterioscle-
rosis, were seen in patients with NARD [29]. Intrarenal arteriosclerosis is related to aging and 
hypertension. Furthermore, a recent study suggested that acute kidney injury (AKI) is a major 
component of CKD in patients with diabetes [30]. Both clinically evident and subclinical AKI can 
damage proximal tubular cells, podocytes, and endothelial cells, and such insults can create an 
apoptotic and inflammatory environment within the kidneys. Atubular glomeruli and glomeru-
lotubular junction abnormalities in diabetes are also related to AKI and can lead to NARD [31].
2.4. Progressive renal decline (PRD)
Diabetic nephropathy has several phenotypes according to clinical and laboratory data; 
among them, PRD is the most serious. Generally, PRD is defined as a >3.5 mL/min/year loss 
in the eGFR in type 1 diabetes and PRD reasonably included NARD. Krolewski reported 
that the prevalence of PRD was 10, 32, and 50% in patients with normoalbuminuria, micro-
albuminuria, and macroalbuminuria, respectively [32]. The recent Scottish Go-DARTS study 
identified biomarkers for PRD: 154 patients with type 2 diabetes and CKD showed a >40% 
decline in eGFR during the 3.5-year study period [33]. In the second Joslin Kidney Study, 
in which PRD was defined as a decrease in eGFR >30% from baseline during ≤5 years of 
follow-up, an early decline in renal function developed in 6 and 18% of patients with nor-
moalbuminuric and microalbuminuric diabetes, respectively [34]. Although the mechanism 
underlying such a decline is unclear, more intensive and personalized treatments are needed 
to prevent progression to ESRD.
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Figure 2. Tubulocentric concept for diabetic nephropathy. (1) Tubulointerstitial damage can cause a disconnect between 
glomerulus and tubule, (2) atubular glomerulus, (3) retrograde trafficking with NMN releasing by proximal tubule 
can contribute glomerulopathy, (4) proximal tubules are vulnerable to hypoxic injury, which can lead to fibrosis and 
apoptosis, (5) reduced retrieval of albumin by impaired tubule resorption is responsible for albuminuria in diabetic 
nephropathy.
The clinical course of diabetic nephropathy varies such that physicians should treat diabetic 
patients using tailored approaches; the term “natural course” may no longer be applicable in 
this era of active interventions. In future, more phenotype-specific approaches informed by 
gene- and proteome-based analyses are needed to improve patient prognosis.
3. Pathophysiology of diabetic nephropathy: tubule versus 
glomerulus
Glomerular dysfunction has long been considered a major driver of diabetic nephropathy. 
Kimmelstiel-Wilson nodules, which are characterized by the formation of diffuse nodular 
lesions of a pink hyaline material in glomerular capillary loops in the glomerulus [35], have 
contributed greatly to the identification of the glomerulus as the main culprit in the develop-
ment of diabetic nephropathy. Diabetes-induced glomerulopathy can be caused by interac-
tions among glomerular endothelial cells, mesangial cells, and podocytes via metabolic and 
hemodynamic perturbations [36]. However, glomerulopathy in diabetes is still not fully 
understood because various cells resident within the glomeruli have different roles in the 
disease process. Furthermore, recent studies revealed that glomerulopathy is preceded by 
tubular dysfunction during the development and progression of diabetic nephropathy [37]. 
These tubulocentric concept addressed in this chapter is summarized in Figure 2.
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3.1. Proximal tubules contribute to glomerulopathy
Pathological changes in the tubulointerstitium that have been linked to diabetic nephropathy 
include the thickening of the tubular basement membrane (TBM), tubular atrophy, interstitial 
fibrosis, and arteriosclerosis, which are closely correlated with the magnitude of renal dysfunc-
tion and albuminuria [38]. Furthermore, such tubulointerstitial damage can cause a disconnect 
between the glomerulus and the proximal tubule, the so-called atubular glomerulus, which is an 
important and a common cause of irreversible CKD progression [39, 40]. These glomerulotubular 
junction abnormalities accompanied by atubular glomerulus have been linked to the development 
and progression of diabetic nephropathy in both type 1 and 2 diabetes [31, 41]. Recent studies 
suggest that the glomerular dysfunction triggered by proximal tubules, the so-called retrograde 
trafficking might be important in diabetic nephropathy [42, 43]. Proximal tubules communicate 
with podocytes by releasing nicotinamide mononucleotide (NMN), and proximal tubule-specific 
Sirt1 protects against diabetic kidney disease by maintaining glomerular NMN concentrations 
and preserving podocyte function [42]. Furthermore, injured proximal tubule epithelium can 
trigger an inflammatory response, and repeated injury results in maladaptive repair. This in turn 
leads to tubulointerstitial fibrosis, tubular atrophy, and, potentially, secondary glomeruloscle-
rosis, which is pathologically similar to classic diabetic nephropathy [44]. Albuminuria, which 
has been primarily considered as a glomerular damage marker, is a sensitive marker, reflecting 
the functional impairment in tubule, alone or in combination with glomerular origin in animal 
nephrotoxicity study [45]. Finally, a substantial evidence from human urinary biomarker data 
supports that proximal tubule damage might have an important role in the development of early 
diabetic nephropathy as a primary cause, not a secondary phenomenon [46].
3.2. Tubular hypoxia hypothesis
In diabetic kidney, proximal tubules are vulnerable to hypoxic injury because of an increased 
oxygen consumption, an impaired oxygen utilization, and a reduced oxygen delivery. Sodium 
reabsorption and gluconeogenesis processes occurring at the proximal tubules consume oxy-
gen. The proximal tubule can be subdivided into three distinct segments (S1, S2, and S3) and 
is adapted for reabsorption. Transport across the tubular epithelium occurs via two routes: 
transcellular transport across luminal and basolateral membranes via Na+, K+ −adenosine 
triphosphatase (ATPase), and paracellular transport through tight junctions and the intercel-
lular space. Glucose enters cells in the proximal tubule via the sodium-glucose cotransporter 
(SGLT), and is extruded from cells by GLUT1 and GLUT2 [47]. High Na+, K+-ATPase activity 
and oxygen consumption levels are needed to reabsorb glucose under high glucose condi-
tions. A recent study showed that SGLT2 inhibitors downregulate Na+ and K+-ATPase activity 
and eventually reduce energy or oxygen requirements [48]. Similar to hepatocytes, epithelial 
cells in proximal tubules perform gluconeogenesis and export glucose into the circulation 
via oxygen- and energy-based processes. In diabetes, renal gluconeogenesis is particularly 
increased in the postprandial or fasting state [49]. Hypoxia induces apoptosis by upregu-
lating Fas expression [50, 51]. Hypoxia stimulates extracellular matrix (ECM) expansion via 
transforming growth factor-β (TGF-β)-dependent and -independent pathways, such as an 
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increased collagen production, a decreased matrix metalloproteinase-2 (MMP-2) activity, and 
an increased tissue inhibitor of metalloproteinase-1 (TIMP-1) expression [52, 53].
Recently, our laboratory studied the role of MMP-2 in diabetic nephropathy. Hyperglycemia-
induced oxidative stress is a major driver of diabetic nephropathy, and high glucose levels 
stimulated the induction of intracellular MMP-2 in HK2 cells; this expression was blocked 
by the NF-κB inhibitor pyrrolidine dithiocarbamate (PDTC) [54]. Intracellular MMP-2 exac-
erbates oxidative stress by inducing the mitochondrial permeability transition, which results 
in tubular epithelial cell-regulated necrosis [55]. Therefore, intracellular MMP-2 is related to 
oxidative stress, and proximal tubular cells are susceptible to hypoxic stress. This may be 
important in the pathogenesis of CKD in DM. The resultant may lead to glomerular change as 
well as tubulointerstitial hypoxia and finally loss of kidney function.
3.3. Intermittent and continuous injurious stimuli lead to proximal tubulopathy  
and CKD
Unlike healthy individuals, patients with diabetes are persistently exposed to various meta-
bolic and hemodynamic factors that sustain the disease state [56]. In addition, AKI frequently 
occurs after various nephrotoxic insults, such as ischemia during cardiac surgery and those 
associated with the administration of contrast media. The proximal tubule is particularly 
vulnerable to the ischemia and toxin-mediated injury that lead to AKI. In a mouse model 
of induced proximal tubule injury, tubular regeneration after a single episode of renal 
epithelium injury was robust and efficient, leading to complete restoration of the kidney 
architecture [45]. However, repeated injury resulted in maladaptive repair, manifested as 
tubulointerstitial fibrosis and tubular atrophy, and with the potential for secondary glomeru-
losclerosis [45]. Thus, these data suggest that the cumulative effects of repeated episodes 
of subclinical AKI arising from injurious stimuli lead to the progressive tubulointerstitial 
fibrosis that is characteristic of CKD, including diabetic nephropathy. Epidemiological and 
clinical observations support a relationship between intermittent AKI and CKD progression 
in diabetic patients [57, 58]. AKI increased the risk of advanced CDK in diabetic patients 
independent of other major risk factors of kidney disease progression, and each episode of 
AKI showed a cumulative dose-response association, doubling the risk of stage 4 CKD [57]. 
In AKI, a low eGFR and/or an elevated albuminuria level are compelling biomarkers for 
major adverse outcomes and death in diabetes [58].
3.4. Tubular contribution to albuminuria
The role of proximal tubules in albuminuria in various renal disorders, including diabetic 
nephropathy, remains controversial. The glomerular filtration barrier has long been consid-
ered largely impermeable to albumin, but recent data suggest that it may not be especially 
important in this process [59]. According to the “retrieval hypothesis,” albuminuria likely has 
a tubular origin, because albumin can be filtered by normal glomeruli in the nephrotic range 
if tubular reabsorption is only partial [60, 61]. Russo et al. [60] reported that more albumin 
was filtered and underwent a rapid retrieval process via transcytosis in proximal tubule cells. 
Therefore, controversy remains regarding the extent of the glomerular filtration of albumin. A 
study of Fanconi syndrome patients with proteinuria reported a markedly impaired albumin 
filtration rate [62]. Collectively, these data suggest that an increased glomerular leakage and 
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an impaired tubular reabsorption are not mutually incompatible, and both are accountable 
for albuminuria in the early diabetic nephropathy [61, 63].
4. Tubular biomarkers of diabetic nephropathy
Classification of diabetic nephropathy based on albuminuria and the eGFR provides prog-
nostic information that is helpful to guide therapeutic decisions. Albuminuria serves as a 
marker of endothelial dysfunction, which is a prognostic factor for renal impairments and a 
high cardiovascular risk [64]. However, its progress is unpredictable, since microalbuminuria 
can regress toward normoalbuminuria, progress toward macroalbuminuria, or remain stable 
[65]. Moreover, diabetic nephropathy can develop in normoalbuminuric patients. In addi-
tion, structural changes in the glomerulus may appear before the onset of microalbuminuria, 
even though microalbuminuria is the established screening tool for diabetic nephropathy 
[66]. Therefore, an intensive search for new blood or urine biomarkers that could improve 
diagnostic and prognostic precision in diabetic nephropathy has recently been reported.
4.1. Classification
Because of emerging evidence supporting tubulocentric concepts in diabetic nephropathy, 
the focus has shifted from glomeruli to proximal tubules, which may contribute to the patho-
genesis of diabetic nephropathy from an early stage. Both functional and structural mark-
ers can be used to detect proximal tubule dysfunction in diabetic nephropathy. One method 
is to detect filtered proteins due to the impaired reabsorption by the proximal tubules. The 
main site for reabsorbing filtered proteins is the proximal tubules and, assuming no secre-
tion or degradation of these proteins through the glomerulus, the more proteins are filtered, 
the higher the urinary excretion rate will be when tubular reabsorption is destroyed. These 
functional tubular biomarkers are low-molecular weight proteins (LMWP) that are mostly 
reabsorbed by the proximal tubules. Another method is to detect proteins released into the 
urine by tubular injury. These urinary proteins are structural tubular biomarkers that come 
directly from tubular cells rather than from plasma. The principal tubular biomarkers in dia-
betic nephropathy are briefly described in Table 1.
4.2. Clinical utility
In tubular proteinuria, the endocytic function of proximal tubule is damaged and a large 
amount of LMWP is detected in the urine. For example, retinol-binding protein 4 is markedly 
elevated when endocytic function is completely eliminated [67]. The cause of an increased 
LMWP excretion in diabetes is usually explained by tubular disease. Animal models suggest 
the pathway that the filtered proteins compete with each other for reabsorption in proximal 
tubules [68]. Clinical studies have also shown that the same pathway leads to the reabsorption 
of albumin and LMWP through glomeruli [69]. The ability of protein reabsorption in proxi-
mal tubules is not known but competition for reabsorption between albumin and LMWP 
may occur. As a result, a slight increase in filtered albumin through glomeruli in the early 
stage of diabetic nephropathy will not cause albuminuria, but an increase in LMWP excre-
tion may be detected indirectly. In other words, early glomerular injury in diabetes may not 
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cause albuminuria if proximal tubules are functioning normally and can reabsorb the excess 
albumin filtered from glomerulus. Other clinical study has also suggested the dissociation 
between albuminuria and increased glomerular leakage of albumin [70].
4.3. Predictive value in clinical studies
Studies using tubular biomarkers showed conflicting results regarding their predictive value 
for GFR decline or the development of albuminuria. In a retrospective analysis, two tubu-
lar injury biomarkers, β2 microglobulin and N-acetyl-β-D glucosaminidase (NAG), did not 
show prognostic utility for detecting GFR decline in type 2 DM (T2DM). However, histologic 
findings of interstitial fibrosis and tubular atrophy (IFTA) did have prognostic benefit. Both 
Functional tubular biomarkers
Albumin 65 kDa Normally filtered very little at the glomerulus. With 
glomerular barrier damage, filtration occurs and followed by 
tubular reabsorption. The resulting albuminuria reflects the 
combined contribution of these two processes.
Cystatin C 13 kDa Filtered by the glomerulus and reabsorbed in the proximal 
tubule. No tubular secretion.
Retinol-binding protein 4 21 kDa
α
1
-microglobulin 26–31 kDa
β
2
-microglobulin 11.8 kDa Filtered by the glomerulus and degraded in the proximal 
tubule via a megalin-dependent pathway. Unstable in urine.
Structural tubular biomarkers
Neutrophil gelatinase-associated 
lipocalin (NGAL)
25 kDa Hyper-produced in the kidney tubules within a few hours 
after renal ischemia-reperfusion injury. It is freely filtered and 
reabsorbed in the proximal tubule.
Kidney injury molecule-1 (KIM-1) 70–80 kDa Cleaved and released into the lumen of the tubule. It 
facilitates repair of the damage by removing cellular debris 
and apoptotic bodies from the injured tubulointerstitial 
compartment.
N-acetyl-β-D glucosaminidase 
(NAG)
>130 kDa Plasma NAG is not filtered through the glomeruli. It is 
released into the urine after renal tubule injury.
Liver-type fatty acid-binding 
protein (L-FABP)
14.2 kDa Associated with structural and functional tubular damage. It 
is freely filtered and reabsorbed in the proximal tubule.
Megalin and Cubilin Megalin 600 kDa 
Cubilin 460 kDa
Most proteins filtered through glomeruli have been identified 
as ligands of megalin, cubilin, or both. The central mechanism 
for protein reabsorption in the proximal tubule.
Alkaline phosphatase (ALP) and
γ-glutamyltransferase (GGT)
ALP 70–120 kDa 
GGT 90 kDa
ALP originates from damaged renal tubules, and its levels 
are associated with the degree of damage. Increased GGT 
excretion in the urine reflects the damage of the brush-border 
membrane and the loss of microvilli.
Table 1. Principal functional and structural tubular biomarkers overexpressed in the urine and explored in clinical 
background of diabetic nephropathy [65–67].
Advances in Nephropathy92
β2 microglobulin and NAG showed a statistically significant correlation with IFTA scores, 
identified as an independent predictor of progression to diabetic nephropathy [71]. In a 
nested case-control study from the diabetes control and complications trial (DCCT), both 
the baseline NAG and increase NAG over time predicted albuminuria independently [72]. A 
3-year prospective study found that type 1 DM (T1DM) patients with high levels of urinary 
neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) had 
a rapid deterioration in GFR. This suggests that tubular injury is important for the progres-
sion of diabetic nephropathy [73]. Fu et al. [74] showed that NGAL increased significantly 
from healthy controls to normoalbuminuric, microalbuminuric, and macroalbuminuric 
patients with T2DM. Conway et al. [75] revealed that the uKIM-1/Cr ratio was elevated in 
T2DM patients with early-stage nephropathy, suggesting tubular injury. The uKIM-1/Cr 
ratio was correlated with a rapid decline in GFR and the severity of proteinuria. Soggiu et al. 
[76]showed that increased RBP4 and α1-microglobulin excretion could predict early-stage 
nephropathy in T1DM. In a retrospective cohort study of 1549 patients with T1DM, liver-type 
fatty acid-binding protein (L-FABP) was a valuable predictor of the progression of diabetic 
nephropathy, irrespective of disease stage [77]. Our laboratory reported that albuminuria is 
significantly correlated with three tubular biomarkers (KIM-1, NGAL, and L-FABP) during 
the early stage of diabetic nephropathy [78]. Our laboratory also reported results obtained 
from 237 patients with T2DM who were measured for NAP and cystatin C. Both biomarkers 
were significantly associated with the decline in eGFR after adjusting for clinical parameters 
[23]. Prospective studies are needed to confirm the clinical utility of tubular biomarkers in the 
early stage of diabetic nephropathy.
4.4. Proteomics and microRNA approach
Recently, many researches using high-throughput proteomics and microRNA (miRNA) 
approaches have been introduced in the field of diabetic nephropathy. These two novel 
approaches for discovering biomarkers can be used to explore diabetic nephropathy through 
multiple pathophysiological processes that can reflect complexed structural and functional 
pathways. Proteomics might provide dynamic profiles, reflecting the complexed pathophysi-
ological changes that occur at different stages of diabetic nephropathy. Proteomics could 
serve as early biomarkers (e.g., CKD273 classifier, a panel consisting of 273 urinary peptides 
[79]) with a good predictive value in the clinical environments [80]. However, proteomic and 
miRNA approaches have yet not been able to replace albuminuria as a marker of diabetic 
nephropathy. miRNAs, which are small noncoding RNAs, are found in extracellular environ-
ment including various body fluids and function in posttranscriptional regulation of gene 
expression. The majority of miRNAs are located within the cell and can serve as a potential 
biomarker. In the urine, miRNAs are more stable in degradation than proteins and are valu-
able for urinary biomarkers. If miRNAs are handled and stored carefully, it could promote 
the discovery of novel urinary biomarkers for diabetic nephropathy. However, they were dif-
ferentially expressed in T1DM and T2DM, and differed according to miRNA sources. In addi-
tion, miRNAs were reported to show gender-specific differences in T1DM [81]. Therefore, 
further studies are needed to optimize the utility of miRNAs in clinical practice.
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5. Proximal tubules as therapeutic targets
Chronic hyperglycemia is an essential component of diabetes and the principal risk factor 
for microvascular complications, including diabetic nephropathy [82]. Patients with diabetes 
also have other risk factors such as obesity, systemic hypertension, and dyslipidemia. Despite 
advances in pharmacologic interventions (e.g., RAS blockers) to control these risk factors, the 
prevalence of diabetic nephropathy continues to rise and remains the leading cause of ESRD 
worldwide [83]. Several novel therapeutic strategies, including dual/triple RAS blockade and 
sulodexide and bardoxolone therapy, have been sought to improve renal outcome in diabetes 
[83]. However, these approaches proved either ineffective or harmful, suggesting that other 
strategies should be sought [84]. The optimal prevention and treatment of CKD in patients 
with diabetes requires the implementation of therapies that specifically consider the role 
played by proximal tubules [85]. The dimension and function of proximal tubules increase 
in response to a higher glucose load. These changes have been linked to an increase in GFR, 
or the so-called diabetic hyperfiltration [85]. Thus, considering the importance of proximal 
tubules in diabetic nephropathy, the development of novel antidiabetic agents, such as SGLT 
2 inhibitors, could yield new tools to prevent diabetic nephropathy.
5.1. Glucose handling by the kidney
The glomeruli of normoglycemic healthy individuals filter ~140–160 g of glucose each day. 
This would result in a urinary loss of energy substrate equal to ~30% of the daily energy 
expenditure if not reclaimed by the renal tubules. Two glucose transporters are responsible 
for renal glucose reabsorption, SGLT1 and SGLT2, which are secondary active co-transporters 
located on the apical membrane that couple glucose reabsorption to sodium reabsorption. 
SGLT2 is located in the early (S1) proximal tubule and accounts for 90% of glucose reab-
sorption, while SGLT1 is located in the more distal part of the proximal tubule (S2/S3) and 
accounts for the remaining 10% [86].
5.2. Glucose reabsorption in the diabetic kidney
In diabetes, hyperglycemia is maintained by the alterations in kidney. Both renal gluco-
neogenesis and glucose reabsorption are increased in diabetic subjects [3]. Hyperglycemia 
increases the amount of glucose filtered through the kidney, and the maximum capacity of 
resorption for glucose is increased by ~30% to ~500–600 g/day in patients with type 2 diabetes 
[84]. If the filtered glucose load exceeds the threshold of proximal tubules in diabetes, glu-
cosuria increases in a linear fashion. These latter changes occur in parallel with upregulated 
SGLT2 expression [87]. More specifically, an increased capacity for glucose transport may 
contribute to the enhanced renal glucose reabsorption seen in diabetes. Upregulated renal 
SGLT2 levels have been reported in both human cells and some animal models of type 1 
and type 2 diabetes [88]. Proximal tubule growth (hypertrophy) is a key feature of early-
stage diabetes, which may explain the increased capacity for renal glucose reabsorption [61]. 
However, it remains unclear whether SGLT2 upregulation is the result of proximal tubule 
hypertrophy in diabetes.
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5.3. SGLT2 inhibition as a therapeutic target
Based on the observation that SGLT2 has an important role in renal glucose reabsorption, the 
proximal tubules of the kidney have been targeted to control the blood glucose. SGLT2 inhibi-
tors are a novel class of antidiabetic drugs that recently entered the market. These medications 
target the kidney proximal tubules to block glucose reabsorption, thereby inducing urinary 
glucose excretion and reducing circulating plasma glucose levels. Their mechanisms of action 
are independent of the action of insulin and beta-cell function.
Phlorizin promotes glucosuria and lowers serum glucose levels in diabetic patients, and 
completely inhibits renal glucose reabsorption in humans [89]. However, the clinical use of 
phlorizin was not pursued due to poor intestinal absorption, low bioavailability, and lack of 
selectivity for SGLT2. Additionally, phlorizin is hydrolyzed to phloretin in the gut, which 
inhibits multiple GLUTs [90]. Thus, the development of SGLT2-specific inhibitor was an 
important breakthrough for therapies targeting renal glucose transport for blood glucose 
management [91].
Currently, the US Food and Drug Administration (FDA) and the European Medicines 
Agency (EMA) have approved three oral SGLT2 inhibitors (canagliflozin, dapagliflozin, 
and empagliflozin) for patients with type 2 diabetes. The SGLT2 inhibitors reduced HbA1C 
by 0.5–0.7% [92]. Additional drugs within this class are under development (Table 2). The 
glucose-lowering effect of SGLT2 inhibitors is closely related to the amount of filtered glu-
cose. Since SGLT2 is responsible for >90% of glucose reabsorption by the kidney, its inhibition 
would be expected to induce a urinary glucose loss close to the filtered load (160–180 g/day 
in normoglycemia). However, SGLT2 inhibitor-associated urinary glucose excretion is only 
~40–80 g/day in healthy individuals and patients with type 2 diabetes, suggesting that SGLT1 
Generic name (trade name) Company Dosing SGLT2/SGLT1 selectivity
Dapagliflozin (Forxiga/Farxiga) AstraZeneca 5–10 mg QD 1400
Canagliflozin (Invokana) Janssen 100–300 mg QD 160
Empagliflozin (Jardiance) Boehringer Ingelheim 10–25 mg QD 5000
Ipragliflozin (Suglat) Astellas Pharma 25–100 mg QD 570
Tofogliflozin (Apleway/Deberza) Sanofi/Kowa 20 mg QD 1875
Luseogliflozin (Lusefi) Taisho Pharmaceutical 2.5–5 mg QD 1770
Ertugliflozin (Steglatro) Merck/Pfizer 1–25 mg QD 2200
Sotagliflozina (N.A.) Lexicon Pharmaceuticals 400 mg QD 20
Remogliflozin etabonate (N.A.) BHV Pharma 100–400 mg QD 1100
Henagliflozin (N.A.) Jiangsu HengRui Medicine 2.5–200 mg QD 1800
SGLT2/SGLT1, sodium-glucose cotransporter 2/sodium-glucose cotransporter 1; QD, once daily; N.A., not applicable. 
aDual SGLT1/2 inhibitor.
Table 2. SGLT2 inhibitors currently approved or in development.
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has an important role in glucose reabsorption under SGLT2 inhibition [88]. SGLT2 inhibi-
tor decreases insulin levels and increases glucagon levels. Thus, SGLT2 inhibitor enhances 
endogenous glucose production, thereby reducing the glucose-lowering efficacy [93].
5.3.1. Effects of SGLT2 inhibitors on renal and cardiovascular outcomes
The EMPA-REG OUTCOME and CANVAS trials investigated the effects of empagliflozin and 
canagliflozin on renal and cardiovascular outcomes in type 2 diabetes patient with high car-
diovascular risk factors and an eGFR of ≥30 mL/min/1.73 m2. In the EMPA-REG OUTCOME 
trial, empagliflozin was associated with a relative risk reduction of 39% in incident or worsen-
ing nephropathy (progression to macroalbuminuria, doubling of serum creatinine level, initia-
tion of renal replacement therapy, or death from renal disease). Moreover, empagliflozin was 
associated with significant risk reductions of 44 and 55% in doubling serum creatinine and the 
initiation of renal replacement therapy, respectively [94]. Empagliflozin was also associated 
with relative risk reductions of 38, 35, and 32% in cardiovascular death, hospitalization for 
heart failure, and death from any cause, respectively. However, there was no risk reduction in 
nonfatal myocardial infarction or in nonfatal stroke [95]. In the CANVAS trial, canagliflozin 
was associated with relative risk reductions of 27 and 40% in the risk of albuminuria progres-
sion and composite renal outcome (40% reduction in eGFR, the need for renal replacement 
therapy, or death from renal cause), respectively [96]. Canagliflozin was also associated with 
a relative risk reduction of 14% in primary cardiovascular composite outcome (cardiovascular 
death, nonfatal myocardial infarction, or nonfatal stroke) [96].
5.3.2. SGLT2 inhibitors: beyond glucose lowering
The beneficial effects of SGLT2 inhibitors could be associated with a glucose-lowering effect. 
However, the small HbA1C reduction is unlikely to explain the rapid onset and effect size. 
Therefore, pleiotropic effects of SGLT2 inhibitor likely played a role (Figure 3). A meta-analysis 
of randomized controlled trial demonstrated that SGLT2 inhibitors decrease the systolic blood 
pressure by 3–6 mmHg in type 2 diabetes patients [92]. The blood pressure-lowering effect 
of SGLT2 inhibitors is partly associated with glycosuria-accompanied osmotic diuresis, which 
increases urine output by 200–600 mL/day. SGLT2 inhibitors also induce natriuresis by decreas-
ing sodium reabsorption in the proximal tubules [84]. Additionally, a positive interaction 
between SGLTs and Na+/H+ exchanger-3 (NHE3), and the inhibition of NHE3 with phlorizin at 
sites associated with a reduced NHE3 activity have been described [97]. Since NHE3 in the early 
proximal tubule is responsible for up to 30% of fractional sodium reabsorption, its potentially 
downregulated activity on SGLT2 inhibition may contribute to natriuresis and subsequent GFR 
and blood pressure lowering; however, this hypothesis requires further study [98].
Clinical trials with SGLT2 inhibitors in patients with type 2 diabetes showed a significant 
weight reduction of ~1.7 kg or 2.4% compared with placebo [99]. While initial weight loss 
appears to result from SGLT2 inhibitor-associated osmotic diuresis, steady-state weight loss 
with SGLT2 inhibitor is thought to be associated with a reduction in body fat mass. In obese 
rat, SGLT2 inhibitor reduces fat mass with a steady calorie loss by increasing lipolysis and 
fatty acid oxidation. SGLT2 inhibitor-induced fat loss is also associated with the increased 
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use of fatty acids instead of glucose as an energy source [100]. SGLT2 inhibitor has also been 
reported to reduce the body weight by reducing visceral and subcutaneous adipose tissue in 
type 2 diabetes patients [101].
Serum uric acid-lowering effect of SGLT2 inhibitor may be associated with the improved 
renal and cardiovascular outcome. SGLT2 inhibitor induces glycosuria, thereby facilitating 
intracellular uric acid exchange via GLUT9 isoform 2 at the proximal tubule, thereby enhanc-
ing urinary excretion of uric acid [102]. However, further study is mandatory to verify the 
precise mechanism of uricosuric effect of SGLT2 inhibitor.
Glomerular hyperfiltration is a detrimental process in diabetic nephropathy and increases 
intraglomerular pressure. The complicated interaction of hyperglycemia-induced structural 
and hemodynamic alterations causes the glomerular hyperfiltration [84]. By inducing baro-
trauma and shear stress, it exacerbates albuminuria and likely contributes to the development 
and progression of CKD [84]. SGLT2 inhibition attenuates primary tubule hyper-reabsorption 
in diabetes and thereby reduces glomerular hyperfiltration. Specifically, SGLT2 inhibitors 
increase sodium delivery at the macula densa and subsequently activate tubuloglomerular 
feedback, which induce afferent arteriolar vasoconstriction and then reduce intraglomerular 
pressure [84]. Recent studies have also confirmed that the SGLT2 inhibitors lower GFR. The 
Figure 3. Pleiotropic effects of sodium-glucose cotransporter (SGLT2) inhibitor. SGLT2 inhibitor may have beneficial 
effects on kidney and heart via several pleiotropic mechanisms: (1) SGLT2 inhibitor blocks glucose hyper-reabsorption in 
the proximal tubule of the diabetic kidney, increasing the tubuloglomerular feedback signal at the macula densa ([Na+/
Cl−/K+]
MD
) and hydrostatic pressure in Bowman’s space (PBOW).This reduces albuminuria and tubular transport work and, thus, renal oxygen consumption by decreasing glomerular hyperfiltration. (2) SGLT2 inhibition reduces insulin 
levels and increases insulin sensitivity and glucagon levels. As a consequence, lipolysis and hepatic gluconeogenesis are 
elevated. These metabolic adaptations reduce fat tissue and body weight. (3) SGLT2 inhibitors induce a modest osmotic 
diuresis, natriuresis, glucosuria, and uricosuria, which can reduce extracellular volume (ECV), blood pressure, serum 
uric acid levels, and body weight.
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empagliflozin decreased the eGFR by 19% in type 1 diabetes patients. The canagliflozin also 
initially decreased GFR in patients with type 2 diabetes [103]. After an initial decrease in eGFR, 
canagliflozin-treated group showed the slower decline of eGFR compared with glimepiride-
treated group over 2 years independently of glycemic effects [104].
5.3.3. SGLT2 inhibitors in diabetic CKD
Nephrons that survive in the advanced stages of CKD are assumed to hyper-filter as a way 
of compensating for the loss of other nephrons. In the short term, SGLT2 inhibitors decreased 
the eGFR in patients with type 2 diabetes and stage 2 or 3 CKD [105, 106]. In the long term, 
the amelioration of glomerular hyperfiltration by SGLT2 inhibitor in CKD may preserve the 
integrity of the remaining nephrons. This concept has also been suggested for angiotensin II 
inhibition. Indeed, both SGLT2 and angiotensin II inhibition confer additional renoprotective 
effect in type 2 diabetes patients with basal eGFR of >30 mL/min/1.73 m2 [94].
5.4. SGLT2 inhibitors: future perspectives
The kidney and cardiovascular protection is likely to be attributed to the pleiotropic effects of 
SGLT2 (EMPA-REG OUTCOME and CANVAS trials). Future research is required to assess 
their ability to improve renal outcome in diabetic patients with more advanced CKD. The 
large trials with different SGLT2 inhibitors are ongoing to confirm whether their beneficial 
effects are drug-specific or represent a class effect. It is also important to investigate their 
effect in patients with nondiabetic kidney disease. In addition, dual SGLT1/2 inhibitors are 
under development to maximize the beneficial effect of SGLT2 inhibitors without causing 
side effects associated with SGLT1 inhibitors.
6. Conclusions
Although researchers are trying to determine the pathophysiology of diabetic nephropathy, 
our understanding remains incomplete. A recent paradigm shift to a tubulocentric concept for 
diabetic nephropathy implies that the proximal tubules have a central role in the disease pro-
cess, rather than being secondarily affected by other components during the development of 
diabetic nephropathy. Representing a considerable step toward shifting the glomerulotubular 
balance, these new perspectives might lead to significant diagnostic and therapeutic advances 
in diabetic nephropathy.
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